Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 12/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3944916 | 0.86 | AOC3 (0.50) | AOC3HPGDHSD17B2HSD17B1PDK1 | |
| SCHEMBL3955465 | 0.81 | AOC3 (0.44) | AOC3HSD17B2HSD17B1 | |
| SCHEMBL3947110 | 0.80 | AOC3 (0.51) | AOC3 | |
| SCHEMBL3945260 | 0.76 | HSD17B2 (0.48) | AOC3HSD17B2HSD17B1PDK1PDK2 | |
| SCHEMBL5762458 | 0.74 | HSD17B2 (0.56) | AOC3HSD17B2HSD17B1 | |
| SCHEMBL5383620 | 0.74 | HSD17B2 (0.56) | AOC3HSD17B2HSD17B1 | |
| SCHEMBL5365662 | 0.74 | HPGD (0.50) | AOC3POLBHPGDRECQLHTT | |
| SCHEMBL3949723 | 0.74 | HSD17B2 (0.40) | AOC3HSD17B2HSD17B1 | |
| SCHEMBL3952266 | 0.74 | HSD17B2 (0.40) | AOC3HSD17B2HSD17B1 | |
| SCHEMBL3952721 | 0.73 | AOC3 (0.47) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285568-B2 | Biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-10-23 | — | — | US | claimed |
| US-20060004048-A1 | Novel biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-05 | — | — | US | claimed |
| US-7582663-B2 | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-09-01 | — | — | US | disclosed |
| US-20080070957-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2008-03-20 | — | — | US | disclosed |
| US-7285568-B2 | Biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-10-23 | — | — | US | disclosed |
| US-20060004048-A1 | Novel biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-05 | — | — | US | disclosed |
| EP-1567509-A2 | BIPHENYL COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004048351-A2 | BIPHENYL COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070957-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | AOC3 2202/4885POLB 1370/4885HPGD 663/4885 |
| US-20060004048-A1 | Novel biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | AOC3 2177/4885POLB 1477/4885HPGD 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.